|
TRBV20OR9-2
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
We present a 59-year-old woman with profound subacute bilateral SNHL including unilateral deafness after immunotherapy based on TCR gene therapy using modified T cells recognizing melanoma antigen recognized by T cells 1 for disseminated melanoma.
|
31295198 |
2019 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
To investigate the changes in the TCR repertoire induced by the anti-CD4 mAb treatment, we performed unbiased high-throughput TCR sequencing in a B16F10 mouse subcutaneous melanoma model.
|
30733724 |
2018 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Herein, we show that a large fraction of the human melanoma epitope tyrosinase reactive TCR transduced T cells that exhibit effector memory (TEM) phenotype and undergo programmed necrosis, or necroptosis, upon TCR restimulation.
|
27750220 |
2016 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Here, we evaluated unique phenotypic traits of CD8⁺ TILs and TCR β chain (TCRβ) clonotypic frequency in melanoma tumors to identify patient-specific repertoires of tumor-reactive CD8⁺ lymphocytes.
|
24667641 |
2014 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
In this review, we discuss the progress and prospects of TCR gene-engineered T cells as a therapeutic strategy for treating patients with melanoma and other cancers.
|
22178904 |
2012 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.
|
20146634 |
2010 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
These results suggest that this highly active tyrosinase-specific TCR could be of value in adoptive cell transfer for melanoma.
|
20427771 |
2010 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
AlteredExpression |
BEFREE |
However, the addition of ABT-737 to either a vaccine strategy involving priming with TRP-2 melanoma antigen peptide-pulsed DC and boosting with recombinant Listeria monocytogenes expressing the same melanoma antigen, or the adoptive transfer of TCR transgenic cells, did not result in superior antitumor activity against B16 murine melanoma.
|
18807035 |
2009 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
AlteredExpression |
BEFREE |
Melanoma involvement of regional nodes is associated with loss of TCR zeta expression that is inversely related to tumor burden.
|
18245524 |
2008 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
A recent trial in humans demonstrated that TCR gene-modified T cells persisted in all and reduced melanoma burden in 2/15 patients.
|
17637721 |
2007 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
AlteredExpression |
BEFREE |
We propose that inducing expression of this highly avid TCR in patient PBMC has the potential to induce tumor regression, as an "off-the-shelf" reagent for allogeneic melanoma patient gene therapy.
|
17056587 |
2006 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
CD8 alpha coreceptor to improve TCR gene transfer to treat melanoma: down-regulation of tumor-specific production of IL-4, IL-5, and IL-10.
|
16818755 |
2006 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
AlteredExpression |
BEFREE |
To better understand the role of individual T cell clones in mediating tumor regression, a 5' RACE technique was used to determine the distribution of TCR beta-chain V region sequences expressed in the transferred cells as well as in tumor samples and circulating lymphocytes from melanoma patients following adoptive cell transfer.
|
15585890 |
2004 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
|
12928363 |
2003 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
These results suggest that lymphocytes genetically engineered to express anti-gp100 TCR may be of value in the adoptive immunotherapy of patients with melanoma.
|
12960359 |
2003 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
To gain insight into these questions, we performed a functional and structural longitudinal analysis of the TCR of circulating CD8(+) T cells specific for the HLA-A2-restricted immunodominant epitope from the melanocyte differentiation Ag Melan-A in a melanoma patient who developed a vigorous and sustained Ag-specific T cell response following vaccination with the corresponding synthetic peptide.
|
11937585 |
2002 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
To address this issue, we compared the T cell receptor (TCR) gene usage, complementary-determining region 3 diversity, and melanoma-associated antigens expression patterns of primary and metastatic melanoma specimens from three patients with partially homologous HLA class-1 types.
|
9856821 |
1998 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
These results suggest a pattern of TCR conservation in CTL selected for recognition of MAGE-1 or BAGE peptides on the autoiogous melanoma.
|
8921424 |
1996 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
AlteredExpression |
BEFREE |
Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas.
|
7614474 |
1995 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
A PCR-based method that determines VDJ junction size patterns in 24 human TCR V beta subfamilies was used to analyze T cells infiltrating sequential malignant melanoma biopsies for the presence of clonal expansions.
|
8077684 |
1994 |
|
TRBV20OR9-2
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
The restricted usage of TCR genes in TIL may indicate that a specific antigen in these melanomas is targeted.
|
2382141 |
1990 |